TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05842785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I dose escalation
Description: The eligible subjects will receive TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II-HNSCC
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II-Advanced melanoma
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II-solid tumors or lymphomas
Description: The eligible subjects will receive RP2D of TSN222 via intratumoral (i.t.) injection on Days 1, 8 and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT04748445

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2/Influenza/RSV RT-PCR
Description: nasal swab
Study: NCT05233943

Intervention type: DEVICE
Intervention: Spinal Mouse and Digital Inclinometer
Description: The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded.

Intervention type: DEVICE
Intervention: Spinal Mouse and Digital Inclinometer
Description: The spinal mouse device is non-invasive and does not have any danger. The posture is evaluated by moving from top to bottom on the spine of the person. Data on the device is transferred to the computer via Bluetooth. The person's posture is evaluated in the sagittal plane by making maximum flexion, neutral stance and maximum extension positions, and in the frontal plane by lateral flexion to the right and left.~Digital Inclinometer; It is a non-invasive measurement tool that investigators measure the position sense of the body, which has two parts, one fixed and one movable. The immobile part of the digital inclinometer is placed at the sacrum and the movable part is placed at the T4 spine level. The person is made 30 degrees of trunk flexion. Then, he is expected to perform 5 repetitions of 30 degrees of trunk flexion with his eyes closed. Deviation angles are recorded.
Study: NCT06291662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printer applications
Description: Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printer applications
Description: Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printer applications
Description: Patients will undergo TC/MRI as per routinary care. Custom 3D-devices will be printed on the basis of these images. The device will be used to establish pre-operative surgical options in terms of tissue/bones demolition/reconstruction.
Study: NCT06333210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody infusions
Description: infusions

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody infusions
Description: infusions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusions
Description: infusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusions
Description: infusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusions
Description: infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab subcutaneous injection
Description: subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo subcutaneous injection
Description: subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous injection
Description: subcutaneous injection
Study: NCT06481852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTT with antibiotic preconditioning + fiber supplementation
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTT with antibiotic preconditioning + placebo supplementation
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MTT with placebo + placebo supplementation.
Description: MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study: NCT06546319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, not to occur on the same day, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
Study: NCT05288725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived MSCs
Description: Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived MSCs
Description: Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived MSCs
Description: Autologous bone marrow aspirate (BMA) is an orthobiologic injection used in knee osteoarthritis therapy. Bone marrow aspirate is harvested from the posterior superior iliac crest (PSIS) of the spine using the Marrow Cellutions kit. BMA will be injected into the knee using ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The corticosteroid is prepared in a 10 ml syringe by combining 1-2 mL Kenalog \[40 mg/dL\], 6-8 mL sterile normal saline, 3-4 mL Ropivicaine 1%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspirate
Description: The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: The Marrow Cellutions kit is an FDA approved device for harvesting bone marrow aspirate.
Study: NCT05480670

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 550 mg Berberine supplement BDS for 3-months + changes in diet/life style.
Study: NCT06028035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BB01
Description: 20 grams minimally processed form of Hemp hulls in the form of a bar/wafer.
Study: NCT05651360

Intervention type: DIAGNOSTIC_TEST
Intervention: low-dose CT
Description: Low-dose CT scan will be performed, not exceeding 30% radiation dose of the standard CT. Low-dose CT images will be reconstructed with TrueFidelity high. The low-dose CT will be performed directly after the standard CT to avoid bias from differences in the timing of the contrast phase.
Study: NCT05923086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORE001
Description: Administration before major meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration before major meal
Study: NCT05228002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sFlt-1/PlGF ratio - Active Comparator: Standard
Description: Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sFlt-1/PlGF ratio - Experimental: Biomarkers
Description: Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation.
Study: NCT05360030

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Naloxone
Description: The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: The volunteer received an intravenous bolus followed by a continuous infusion of naloxone, which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: The volunteer received an intravenous bolus followed by a continuous infusion of placebo (saline), which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: The volunteer received an intravenous bolus followed by a continuous infusion of ketamine, which was continued throughout the pcTBS session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pcTBS of M1
Description: Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left M1 at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pcTBS of DLPFC
Description: Prolonged continuous theta-burst stimulation (pcTBS) was administered to the left DLPFC at 80% RMT, consisting of a burst of 3 pulses given at 50 Hz repeated every 5 Hz. A total of 1,200 pulses were delivered with the TMS coil positioned in a posterior-anterior (PA) direction parallel to the midline

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM stimulation
Description: The Sham stimulation was delivered using the same pcTBS protocol, with the coil being flipped 90◦to the scalp so that the magnetic field would be delivered away from the scalp
Study: NCT05254444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing
Description: Multi-tiered nutrition social marketing intervention focused on sustainable fish nutrition, dietary diversity and food safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social marketing + gear modification
Description: Multi-tiered nutrition social marketing intervention plus fishing gear modification (basket trap) and training.
Study: NCT05907486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine
Description: 8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2mg/kg, day-7 to day -5, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 3.2mg/kg, day-7 to day -5, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2, day -8, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 2g/m2, day -8, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1.8g/m2, day -4 to day -3, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1.8g/m2, day -4 to day -3, intravenously
Study: NCT06023602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic cetrorelix acetate
Description: Generic cetrorelix acetate (0.25 mg SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference cetrorelix acetate
Description: reference cetrorelix acetate (0.25 mg SC)
Study: NCT05452499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education and therapeutic exercise
Description: Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).
Study: NCT05121103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZM0414
Description: Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
Study: NCT05896566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
Study: NCT04715919

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest Computed Tomography
Description: Evaluation of Lung Structure

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest Computed Tomography
Description: Evaluation of Lung Structure

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests
Description: Respiratory Capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests
Description: Respiratory Capacity

Intervention type: OTHER
Intervention: Six Minutes Walk Test
Description: Exercise Capacity
Study: NCT05896566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
Study: NCT04715919

Intervention type: OTHER
Intervention: Six Minutes Walk Test
Description: Exercise Capacity
Study: NCT05354063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 μg dose of SYS6006
Description: 20 μg dose of SYS6006 vaccine IM on day 0 and day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 μg dose of SYS6006
Description: 30 μg dose of SYS6006 vaccine IM on day 0 and day 21.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IM on day 0 and day 21.
Study: NCT05896566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
Study: NCT04715919

Intervention type: OTHER
Intervention: Quality of Life
Description: Physical disability assessment tool

Intervention type: OTHER
Intervention: Quality of Life
Description: Physical disability assessment tool
Study: NCT05563363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-like treatment in patients' home
Description: Hospital-like treatment in patients' home. Caregivers, medical doctors and social workers will make several visits per day to the patients' home. 24/7 contact is available.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard inpatient treatment
Description: Inpatient treatment on addiction ward
Study: NCT05796180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: sexual health counseling based on the BETTER model
Description: The content of the research will be discussed by face-to-face interviews with women who gave birth vaginally and applied to the hospital for birth control 8-10 weeks after delivery. Pre-evaluation forms will be applied to women who have agreed to participate in the study to evaluate the inclusion criteria. Women who meet the inclusion criteria will be divided into experimental-control groups using the block randomization method.~An appointment will be made for interviews with the women in the experimental group. It is planned that these meetings will be held in the form of online video calls and will last an average of 45 minutes. The final tests will be held 8 weeks after the online meetings are over.
Study: NCT05023135

Intervention type: DEVICE
Intervention: DeepView SnapShot Portable (DV-SSP)
Description: DV-SSP assistive imaging to collect observational data
Study: NCT05965843

Intervention type: OTHER
Intervention: underling disease
Description: Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.

Intervention type: OTHER
Intervention: underling disease
Description: Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.

Intervention type: OTHER
Intervention: underling disease
Description: Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.

Intervention type: OTHER
Intervention: underling disease
Description: Nowadays Covid-19 virus has become milder than before however severe outcomes still happen in people with underlying diseases after infection.~For example, previous research indicated cirrhosis was an independent predictor for COVID-19 mortality.~More efforts shoud be make to explore the association between underlying diseases and severe COVID-19.
Study: NCT06315140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: The intervention will build on the 11-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity. Working with the Ramapough-leased Munsee Three Sisters Medicinal farm (growing produce/crops on clean soil) will provide the tribe with nutrition-rich foods and recipes for nutritious cooking. The interventions aims to return healthy soil on the farm allowing for healthy plant production.